In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biovail pays Aventis $409.5mm for Cardizem

Executive Summary

Biovail (drug products utilizing advanced drug delivery technologies) has agreed to pay Aventis Pharmaceuticals $409.5mm for N. American rights to sell its line of Cardizem (diltiazem) hypertension and angina products. It paid Aventis (uf)$239.5mm up front, and will turn over the remaining fees in equal, quarterly payments throughout 2001.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Product Purchase

Related Companies